The single-arm, phase II NACI study (NCT04516616) [55] investigated the activity and safety of the PD1 inhibitor camrelizumab combined with neoadjuvant chemotherapy followed by radical hysterectomy in patients with PD-L1-positive locally advanced cervical cancer at FIGO 2018 stage IB3, IIA2, or IIB/IIIC1 with a tumor diameter ≥ 4 cm. The gene discussed is PDCD1; the disease is cervical carcinoma.